ChloroquineV1, Istex, Corpus, bibRecord, 002374

Sarcoidosis associated with vemurafenib

Identifieur interne : 002374 ( Istex/Corpus ); précédent : 002373; suivant : 002375

Sarcoidosis associated with vemurafenib

Auteurs : A. Adam ; L. Thomas ; N. Bories ; D. Zaharia ; B. Balme ; N. Freymond ; S. Dalle

Source :

British Journal of Dermatology [ 0007-0963 ] ; 2013-07.

RBID : ISTEX:4404FDE205BB5B6F1B63492B92010DA0F46F0BDA

English descriptors

Teeft :
- Angiosarcoma, Axillary, Braf, British association, British journal, Bronchoalveolar lavage, Case report, Cetuximab, Chemotherapy, Cutaneous, Dermatology, Funding sources, Grand revoyet, Growth factor, Growth factors, Hospices civils, Infectious aetiology, Inhibitor, Kinase, Melanoma, Metastasis, Metastatic, Metastatic melanoma, Monoclonal antibody, Mutation, Node, Oncol, Positive nodes, Radiotherapy, Receptor, Sarcoidosis, Sarcoma, Selective braf inhibitor, Skin lesion, Soft tissue sarcoma, Squamous cell carcinoma, Sunitinib, Surg oncol, Vemurafenib.

Url:

https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/fulltext.pdf

DOI: 10.1111/bjd.12268

Links to Exploration step

ISTEX:4404FDE205BB5B6F1B63492B92010DA0F46F0BDA

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sarcoidosis associated with vemurafenib</title>
<author><name sortKey="Adam, A" sort="Adam, A" uniqKey="Adam A" first="A." last="Adam">A. Adam</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Thomas, L" sort="Thomas, L" uniqKey="Thomas L" first="L." last="Thomas">L. Thomas</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bories, N" sort="Bories, N" uniqKey="Bories N" first="N." last="Bories">N. Bories</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Zaharia, D" sort="Zaharia, D" uniqKey="Zaharia D" first="D." last="Zaharia">D. Zaharia</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Balme, B" sort="Balme, B" uniqKey="Balme B" first="B." last="Balme">B. Balme</name>
<affiliation><mods:affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Freymond, N" sort="Freymond, N" uniqKey="Freymond N" first="N." last="Freymond">N. Freymond</name>
<affiliation><mods:affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dalle, S" sort="Dalle, S" uniqKey="Dalle S" first="S." last="Dalle">S. Dalle</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Cancer Research Center of Lyon, 8 avenue de Rockefeller, 69008 Lyon, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence: Stéphane Dalle.E‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: stephane.dalle@chu-lyon.fr</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4404FDE205BB5B6F1B63492B92010DA0F46F0BDA</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1111/bjd.12268</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002374</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002374</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Sarcoidosis associated with vemurafenib</title>
<author><name sortKey="Adam, A" sort="Adam, A" uniqKey="Adam A" first="A." last="Adam">A. Adam</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Thomas, L" sort="Thomas, L" uniqKey="Thomas L" first="L." last="Thomas">L. Thomas</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bories, N" sort="Bories, N" uniqKey="Bories N" first="N." last="Bories">N. Bories</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Zaharia, D" sort="Zaharia, D" uniqKey="Zaharia D" first="D." last="Zaharia">D. Zaharia</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Balme, B" sort="Balme, B" uniqKey="Balme B" first="B." last="Balme">B. Balme</name>
<affiliation><mods:affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Freymond, N" sort="Freymond, N" uniqKey="Freymond N" first="N." last="Freymond">N. Freymond</name>
<affiliation><mods:affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dalle, S" sort="Dalle, S" uniqKey="Dalle S" first="S." last="Dalle">S. Dalle</name>
<affiliation><mods:affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Cancer Research Center of Lyon, 8 avenue de Rockefeller, 69008 Lyon, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence: Stéphane Dalle.E‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: stephane.dalle@chu-lyon.fr</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="ISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<imprint><biblScope unit="vol">169</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="206">206</biblScope>
<biblScope unit="page" to="208">208</biblScope>
<biblScope unit="page-count">3</biblScope>
<date type="published" when="2013-07">2013-07</date>
</imprint>
<idno type="ISSN">0007-0963</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0007-0963</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Angiosarcoma</term>
<term>Axillary</term>
<term>Braf</term>
<term>British association</term>
<term>British journal</term>
<term>Bronchoalveolar lavage</term>
<term>Case report</term>
<term>Cetuximab</term>
<term>Chemotherapy</term>
<term>Cutaneous</term>
<term>Dermatology</term>
<term>Funding sources</term>
<term>Grand revoyet</term>
<term>Growth factor</term>
<term>Growth factors</term>
<term>Hospices civils</term>
<term>Infectious aetiology</term>
<term>Inhibitor</term>
<term>Kinase</term>
<term>Melanoma</term>
<term>Metastasis</term>
<term>Metastatic</term>
<term>Metastatic melanoma</term>
<term>Monoclonal antibody</term>
<term>Mutation</term>
<term>Node</term>
<term>Oncol</term>
<term>Positive nodes</term>
<term>Radiotherapy</term>
<term>Receptor</term>
<term>Sarcoidosis</term>
<term>Sarcoma</term>
<term>Selective braf inhibitor</term>
<term>Skin lesion</term>
<term>Soft tissue sarcoma</term>
<term>Squamous cell carcinoma</term>
<term>Sunitinib</term>
<term>Surg oncol</term>
<term>Vemurafenib</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>sarcoidosis</json:string>
<json:string>vemurafenib</json:string>
<json:string>metastatic</json:string>
<json:string>sunitinib</json:string>
<json:string>braf</json:string>
<json:string>melanoma</json:string>
<json:string>angiosarcoma</json:string>
<json:string>cetuximab</json:string>
<json:string>metastatic melanoma</json:string>
<json:string>node</json:string>
<json:string>sarcoma</json:string>
<json:string>oncol</json:string>
<json:string>metastasis</json:string>
<json:string>dermatology</json:string>
<json:string>cutaneous</json:string>
<json:string>receptor</json:string>
<json:string>kinase</json:string>
<json:string>chemotherapy</json:string>
<json:string>radiotherapy</json:string>
<json:string>axillary</json:string>
<json:string>mutation</json:string>
<json:string>selective braf inhibitor</json:string>
<json:string>british association</json:string>
<json:string>growth factor</json:string>
<json:string>surg oncol</json:string>
<json:string>british journal</json:string>
<json:string>case report</json:string>
<json:string>soft tissue sarcoma</json:string>
<json:string>positive nodes</json:string>
<json:string>infectious aetiology</json:string>
<json:string>funding sources</json:string>
<json:string>squamous cell carcinoma</json:string>
<json:string>skin lesion</json:string>
<json:string>monoclonal antibody</json:string>
<json:string>grand revoyet</json:string>
<json:string>hospices civils</json:string>
<json:string>growth factors</json:string>
<json:string>bronchoalveolar lavage</json:string>
<json:string>inhibitor</json:string>
</teeft>
</keywords>
<author><json:item><name>A. Adam</name>
<affiliations><json:string>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</json:string>
<json:string>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</json:string>
</affiliations>
</json:item>
<json:item><name>L. Thomas</name>
<affiliations><json:string>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</json:string>
<json:string>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</json:string>
</affiliations>
</json:item>
<json:item><name>N. Bories</name>
<affiliations><json:string>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</json:string>
</affiliations>
</json:item>
<json:item><name>D. Zaharia</name>
<affiliations><json:string>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</json:string>
<json:string>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</json:string>
</affiliations>
</json:item>
<json:item><name>B. Balme</name>
<affiliations><json:string>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</json:string>
</affiliations>
</json:item>
<json:item><name>N. Freymond</name>
<affiliations><json:string>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</json:string>
</affiliations>
</json:item>
<json:item><name>S. Dalle</name>
<affiliations><json:string>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</json:string>
<json:string>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</json:string>
<json:string>Cancer Research Center of Lyon, 8 avenue de Rockefeller, 69008 Lyon, France</json:string>
<json:string>Correspondence: Stéphane Dalle.E‐mail:</json:string>
<json:string>E-mail: stephane.dalle@chu-lyon.fr</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>BRAF</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>melanoma</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>sarcoidosis</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>vemurafenib</value>
</json:item>
</subject>
<articleId><json:string>BJD12268</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-K1LCD9FN-J</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>letter</json:string>
</originalGenre>
<qualityIndicators><score>3.873</score>
<pdfWordCount>1861</pdfWordCount>
<pdfCharCount>12597</pdfCharCount>
<pdfVersion>1.6</pdfVersion>
<pdfPageCount>3</pdfPageCount>
<pdfPageSize>595.163 x 779.415 pts</pdfPageSize>
<pdfWordsPerPage>620</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>1</abstractWordCount>
<abstractCharCount>0</abstractCharCount>
<keywordCount>4</keywordCount>
</qualityIndicators>
<title>Sarcoidosis associated with vemurafenib</title>
<pmid><json:string>23834124</json:string>
</pmid>
<genre><json:string>review-article</json:string>
</genre>
<host><title>British Journal of Dermatology</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1365-2133</json:string>
</doi>
<issn><json:string>0007-0963</json:string>
</issn>
<eissn><json:string>1365-2133</json:string>
</eissn>
<publisherId><json:string>BJD</json:string>
</publisherId>
<volume>169</volume>
<issue>1</issue>
<pages><first>206</first>
<last>208</last>
<total>3</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Correspondence</value>
</json:item>
<json:item><value>Correspondence</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date><json:string>2013-03-27</json:string>
</date>
<geogName></geogName>
<orgName></orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName></persName>
<placeName></placeName>
<ref_url></ref_url>
<ref_bibl></ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/WNG-K1LCD9FN-J</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - dermatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - dermatology & venereal diseases</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Dermatology</json:string>
</scopus>
</categories>
<publicationDate>2013</publicationDate>
<copyrightDate>2013</copyrightDate>
<doi><json:string>10.1111/bjd.12268</json:string>
</doi>
<id>4404FDE205BB5B6F1B63492B92010DA0F46F0BDA</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Sarcoidosis associated with vemurafenib</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher>
<availability><licence>© 2013 The Authors BJD © 2013 British Association of Dermatologists</licence>
</availability>
<date type="published" when="2013-07"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="review-article" source="letter" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Sarcoidosis associated with vemurafenib</title>
<author xml:id="author-0000"><persName><forename type="first">A.</forename>
<surname>Adam</surname>
</persName>
<affiliation><orgName type="division">Unit of Dermatology</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐ Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
<affiliation><orgName type="institution">Université Claude Bernard Lyon 1</orgName> 
                        <address><street>Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller</street> 
                           <postCode>69008</postCode> 
                           <settlement>Lyon</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">L.</forename>
<surname>Thomas</surname>
</persName>
<affiliation><orgName type="division">Unit of Dermatology</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐ Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
<affiliation><orgName type="institution">Université Claude Bernard Lyon 1</orgName> 
                        <address><street>Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller</street> 
                           <postCode>69008</postCode> 
                           <settlement>Lyon</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">N.</forename>
<surname>Bories</surname>
</persName>
<affiliation><orgName type="division">Unit of Dermatology</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐ Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">D.</forename>
<surname>Zaharia</surname>
</persName>
<affiliation><orgName type="division">Unit of Dermatology</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐ Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
<affiliation><orgName type="institution">Université Claude Bernard Lyon 1</orgName> 
                        <address><street>Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller</street> 
                           <postCode>69008</postCode> 
                           <settlement>Lyon</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">B.</forename>
<surname>Balme</surname>
</persName>
<affiliation><orgName type="division">Unit of Pathology and Unit of Pneumonology</orgName> 
                        <orgName type="institution">Hospices Civils de Lyon</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">N.</forename>
<surname>Freymond</surname>
</persName>
<affiliation><orgName type="division">Unit of Pathology and Unit of Pneumonology</orgName> 
                        <orgName type="institution">Hospices Civils de Lyon</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0006" role="corresp"><persName><forename type="first">S.</forename>
<surname>Dalle</surname>
</persName>
<affiliation><orgName type="division">Unit of Dermatology</orgName> 
                        <orgName type="institution">Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName> 
                        <address><street>165 chemin du grand Revoyet</street> 
                           <postCode>69495</postCode> 
                           <settlement>Pierre‐ Bénite</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
<affiliation><orgName type="institution">Université Claude Bernard Lyon 1</orgName> 
                        <address><street>Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller</street> 
                           <postCode>69008</postCode> 
                           <settlement>Lyon</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
<affiliation><orgName type="institution">Cancer Research Center of Lyon</orgName> 
                        <orgName type="institution">8 avenue de Rockefeller</orgName> 
                        <orgName type="institution">69008 Lyon</orgName> 
                        <address><country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<idno type="istex">4404FDE205BB5B6F1B63492B92010DA0F46F0BDA</idno>
<idno type="ark">ark:/67375/WNG-K1LCD9FN-J</idno>
<idno type="DOI">10.1111/bjd.12268</idno>
<idno type="unit">BJD12268</idno>
<idno type="toTypesetVersion">file:BJD.BJD12268.pdf</idno>
</analytic>
<monogr><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="pISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<idno type="book-DOI">10.1111/(ISSN)1365-2133</idno>
<idno type="book-part-DOI">10.1111/bjd.2013.169.issue-1</idno>
<idno type="product">BJD</idno>
<imprint><biblScope unit="vol">169</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="206">206</biblScope>
<biblScope unit="page" to="208">208</biblScope>
<biblScope unit="page-count">3</biblScope>
<date type="published" when="2013-07"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><textClass><keywords><term xml:id="bjd12268-kwd-0001"><hi rend="fc">BRAF</hi>
</term>
<term xml:id="bjd12268-kwd-0002">melanoma</term>
<term xml:id="bjd12268-kwd-0003">sarcoidosis</term>
<term xml:id="bjd12268-kwd-0004">vemurafenib</term>
</keywords>
<keywords rend="articleCategory"><term>Correspondence</term>
</keywords>
<keywords rend="tocHeading1"><term>Correspondence</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component type="serialArticle" version="2.0" xml:id="bjd12268" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2133</doi>
<issn type="print">0007-0963</issn>
<issn type="electronic">1365-2133</issn>
<idGroup><id type="product" value="BJD"></id>
</idGroup>
<titleGroup><title sort="BRITISH JOURNAL OF DERMATOLOGY" type="main">British Journal of Dermatology</title>
<title type="short">Br J Dermatol</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="07101"><doi origin="wiley">10.1111/bjd.2013.169.issue-1</doi>
<copyright ownership="thirdParty">Copyright © 2013 British Association of Dermatologists</copyright>
<numberingGroup><numbering number="169" type="journalVolume">169</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2013-07">July 2013</coverDate>
</publicationMeta>
<publicationMeta level="unit" position="46" status="forIssue" type="letter"><doi>10.1111/bjd.12268</doi>
<idGroup><id type="unit" value="BJD12268"></id>
</idGroup>
<countGroup><count number="3" type="pageTotal"></count>
</countGroup>
<titleGroup><title type="articleCategory">Correspondence</title>
<title type="tocHeading1">Correspondence</title>
</titleGroup>
<copyright ownership="thirdParty">© 2013 The Authors BJD © 2013 British Association of Dermatologists</copyright>
<eventGroup><event agent="SPS" date="2013-03-27" type="xmlCreated"></event>
<event type="firstOnline" date="2013-07-08"></event>
<event type="publishedOnlineFinalForm" date="2013-07-08"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-03"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">206</numbering>
<numbering type="pageLast">208</numbering>
</numberingGroup>
<correspondenceTo><lineatedText><line>Correspondence: Stéphane Dalle.</line>
<line>E‐mail: <email>stephane.dalle@chu-lyon.fr</email>
</line>
</lineatedText>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:BJD.BJD12268.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><titleGroup><title type="main">Sarcoidosis associated with vemurafenib</title>
<title type="shortAuthors">Correspondence</title>
</titleGroup>
<creators><creator affiliationRef="#bjd12268-aff-0001 #bjd12268-aff-0002" creatorRole="author" xml:id="bjd12268-cr-0001"><personName><givenNames>A.</givenNames>
 <familyName>Adam</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0001 #bjd12268-aff-0002" creatorRole="author" xml:id="bjd12268-cr-0002"><personName><givenNames>L.</givenNames>
 <familyName>Thomas</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0001" creatorRole="author" xml:id="bjd12268-cr-0003"><personName><givenNames>N.</givenNames>
 <familyName>Bories</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0001 #bjd12268-aff-0002" creatorRole="author" xml:id="bjd12268-cr-0004"><personName><givenNames>D.</givenNames>
 <familyName>Zaharia</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0003" creatorRole="author" xml:id="bjd12268-cr-0005"><personName><givenNames>B.</givenNames>
 <familyName>Balme</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0003" creatorRole="author" xml:id="bjd12268-cr-0006"><personName><givenNames>N.</givenNames>
 <familyName>Freymond</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd12268-aff-0001 #bjd12268-aff-0002 #bjd12268-aff-0004" corresponding="yes" creatorRole="author" xml:id="bjd12268-cr-0007"><personName><givenNames>S.</givenNames>
 <familyName>Dalle</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation countryCode="FR" type="organization" xml:id="bjd12268-aff-0001"><orgDiv>Unit of Dermatology</orgDiv>
 <orgName>Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon</orgName>
 <address><street>165 chemin du grand Revoyet</street>
 <postCode>69495</postCode>
 <city>Pierre‐ Bénite</city>
 <country>France</country>
</address>
</affiliation>
<affiliation countryCode="FR" type="organization" xml:id="bjd12268-aff-0002"><orgName>Université Claude Bernard Lyon 1</orgName>
 <address><street>Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller</street>
 <postCode>69008</postCode>
 <city>Lyon</city>
 <country>France</country>
</address>
</affiliation>
<affiliation countryCode="FR" type="organization" xml:id="bjd12268-aff-0003"><orgDiv>Unit of Pathology and Unit of Pneumonology</orgDiv>
 <orgName>Hospices Civils de Lyon</orgName>
 <orgName>Centre Hospitalier Lyon‐Sud</orgName>
 <address><street>165 chemin du grand Revoyet</street>
 <postCode>69495</postCode>
 <city>Pierre‐Bénite</city>
 <country>France</country>
</address>
</affiliation>
<affiliation countryCode="FR" type="organization" xml:id="bjd12268-aff-0004"><orgName>Cancer Research Center of Lyon</orgName>
 <orgName>8 avenue de Rockefeller</orgName>
 <orgName>69008 Lyon</orgName>
 <address><country>France</country>
</address>
</affiliation>
</affiliationGroup>
<keywordGroup type="author"><keyword xml:id="bjd12268-kwd-0001"><fc>BRAF</fc>
</keyword>
<keyword xml:id="bjd12268-kwd-0002">melanoma</keyword>
<keyword xml:id="bjd12268-kwd-0003">sarcoidosis</keyword>
<keyword xml:id="bjd12268-kwd-0004">vemurafenib</keyword>
</keywordGroup>
</contentMeta>
<noteGroup xml:id="bjd12258-ntgp-0001"><note numbered="no" xml:id="bjd12268-note-0001">Funding sources: This work is supported in part by grants from Lyon 1 University (to L.T.), the Hospices Civils de Lyon (to L.T.) and the Ligue Contre le Cancer du Rhone (to L.T.).</note>
<note numbered="no" xml:id="bjd12268-note-0002">Conflicts of interest: none declared.</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Sarcoidosis associated with vemurafenib</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Sarcoidosis associated with vemurafenib</title>
</titleInfo>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Adam</namePart>
<affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</affiliation>
<affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L.</namePart>
<namePart type="family">Thomas</namePart>
<affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</affiliation>
<affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N.</namePart>
<namePart type="family">Bories</namePart>
<affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D.</namePart>
<namePart type="family">Zaharia</namePart>
<affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</affiliation>
<affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">B.</namePart>
<namePart type="family">Balme</namePart>
<affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N.</namePart>
<namePart type="family">Freymond</namePart>
<affiliation>Unit of Pathology and Unit of Pneumonology, Hospices Civils de Lyon, Centre Hospitalier Lyon‐Sud, 165 chemin du grand Revoyet, 69495, Pierre‐Bénite, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">S.</namePart>
<namePart type="family">Dalle</namePart>
<affiliation>Unit of Dermatology, Centre Hospitalier Lyon‐Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, 69495, Pierre‐ Bénite, France</affiliation>
<affiliation>Université Claude Bernard Lyon 1, Faculté de Médecine Lyon‐Est 8 avenue de Rockefeller, 69008, Lyon, France</affiliation>
<affiliation>Cancer Research Center of Lyon, 8 avenue de Rockefeller, 69008 Lyon, France</affiliation>
<affiliation>Correspondence: Stéphane Dalle.E‐mail:</affiliation>
<affiliation>E-mail: stephane.dalle@chu-lyon.fr</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="letter" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre>
<originInfo><publisher>Blackwell Publishing Ltd</publisher>
<dateIssued encoding="w3cdtf">2013-07</dateIssued>
<dateCreated encoding="w3cdtf">2013-03-27</dateCreated>
<copyrightDate encoding="w3cdtf">2013</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<subject><genre>keywords</genre>
<topic>BRAF</topic>
<topic>melanoma</topic>
<topic>sarcoidosis</topic>
<topic>vemurafenib</topic>
</subject>
<relatedItem type="host"><titleInfo><title>British Journal of Dermatology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Br J Dermatol</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><genre>article-category</genre>
<topic>Correspondence</topic>
<topic>Correspondence</topic>
</subject>
<identifier type="ISSN">0007-0963</identifier>
<identifier type="eISSN">1365-2133</identifier>
<identifier type="DOI">10.1111/(ISSN)1365-2133</identifier>
<identifier type="PublisherID">BJD</identifier>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>169</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>206</start>
<end>208</end>
<total>3</total>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="bjd12268-cit-0001"><titleInfo><title>Inhibition of mutated, activated BRAF in metastatic melanoma</title>
</titleInfo>
<name type="personal"><namePart type="given">KT</namePart>
<namePart type="family">Flaherty</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">I</namePart>
<namePart type="family">Puzanov</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">KB</namePart>
<namePart type="family">Kim</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809–19.</note>
<part><date>2010</date>
<detail type="volume"><caption>vol.</caption>
<number>363</number>
</detail>
<extent unit="pages"><start>809</start>
<end>19</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>N Engl J Med</title>
</titleInfo>
<part><date>2010</date>
<detail type="volume"><caption>vol.</caption>
<number>363</number>
</detail>
<extent unit="pages"><start>809</start>
<end>19</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd12268-cit-0002"><titleInfo><title>Vemurafenib in melanoma with BRAF V600E mutation</title>
</titleInfo>
<name type="personal"><namePart type="given">S</namePart>
<namePart type="family">Dalle</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N</namePart>
<namePart type="family">Poulalhon</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L</namePart>
<namePart type="family">Thomas</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 365:1448–9; author reply 50.</note>
<part><date>2011</date>
<detail type="volume"><caption>vol.</caption>
<number>365</number>
</detail>
<extent unit="pages"><start>1448</start>
<end>9</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>N Engl J Med</title>
</titleInfo>
<part><date>2011</date>
<detail type="volume"><caption>vol.</caption>
<number>365</number>
</detail>
<extent unit="pages"><start>1448</start>
<end>9</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd12268-cit-0003"><titleInfo><title>Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment‐related skin toxicities</title>
</titleInfo>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Sinha</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">K</namePart>
<namePart type="family">Edmonds</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JA</namePart>
<namePart type="family">Newton‐Bishop</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Sinha R, Edmonds K, Newton‐Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment‐related skin toxicities. Br J Dermatol 2012; 167:987–94.</note>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>167</number>
</detail>
<extent unit="pages"><start>987</start>
<end>94</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Br J Dermatol</title>
</titleInfo>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>167</number>
</detail>
<extent unit="pages"><start>987</start>
<end>94</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd12268-cit-0004"><titleInfo><title>Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti‐CTLA‐4 monoclonal antibody and selective BRAF inhibitor</title>
</titleInfo>
<name type="personal"><namePart type="given">S</namePart>
<namePart type="family">Wilgenhof</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">V</namePart>
<namePart type="family">Morlion</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">AC</namePart>
<namePart type="family">Seghers</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Wilgenhof S, Morlion V, Seghers AC et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti‐CTLA‐4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012; 32:1355–9.</note>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>32</number>
</detail>
<extent unit="pages"><start>1355</start>
<end>9</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Anticancer Res</title>
</titleInfo>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>32</number>
</detail>
<extent unit="pages"><start>1355</start>
<end>9</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd12268-cit-0005"><titleInfo><title>Mitogen‐activated protein kinase phosphatase (MKP)‐1 in immunology, physiology, and disease</title>
</titleInfo>
<name type="personal"><namePart type="given">LM</namePart>
<namePart type="family">Wancket</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">WJ</namePart>
<namePart type="family">Frazier</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Y</namePart>
<namePart type="family">Liu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Wancket LM, Frazier WJ, Liu Y. Mitogen‐activated protein kinase phosphatase (MKP)‐1 in immunology, physiology, and disease. Life Sci 2012; 90:237–48.</note>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>90</number>
</detail>
<extent unit="pages"><start>237</start>
<end>48</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Life Sci</title>
</titleInfo>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>90</number>
</detail>
<extent unit="pages"><start>237</start>
<end>48</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<identifier type="istex">4404FDE205BB5B6F1B63492B92010DA0F46F0BDA</identifier>
<identifier type="ark">ark:/67375/WNG-K1LCD9FN-J</identifier>
<identifier type="DOI">10.1111/bjd.12268</identifier>
<identifier type="ArticleID">BJD12268</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2013 British Association of Dermatologists© 2013 The Authors BJD © 2013 British Association of Dermatologists</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Converted from  (version ) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-K1LCD9FN-J/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002374 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002374 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:4404FDE205BB5B6F1B63492B92010DA0F46F0BDA
   |texte=   Sarcoidosis associated with vemurafenib
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Sarcoidosis associated with vemurafenib

Sarcoidosis associated with vemurafenib

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri